Literature DB >> 16426264

Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.

M Linde1, A Mellberg, C Dahlöf.   

Abstract

Over the years the paradigm of treating early during the migraine attack has become well established in clinical practice. It is also recommended that the 5-HT(1B/1D) agonists be administered early during the migraine attack for efficacy. This is because it has been proposed that most migraineurs are less responsive to delayed treatment, owing to the development of central sensitization of the pain transmission. The main objective of this prospective, cross-over study at a specialist clinic was to evaluate if these recommendations should also apply to the subcutaneous formulation of sumatriptan. Results are based on 20 adult International Headache Society migraineurs. Two attacks (n=40) were treated with 6 mg subcutaneous sumatriptan as early as possible after the onset of migraine headache and two attacks (n=40) as late as the patients could bear. The median intra-individual difference between the two strategies in time from first occurrence of pain to injection was 5.7 h and the median intra-individual difference in pain intensity at the time of injection was 29 visual analogue units. No significant differences were found in time to freedom from pain, pain severity at 1 and 2 h, area under the curves from injection to pain free or in headache recurrence after injection. At the end of the study, most of the patients claimed that their medication was as effective when given early as when given late in the course of the attack. The discrepancy between our present findings and retrospective analyses of trials on oral triptans probably has more to do with the less disturbed pharmacokinetics early during the migraine attack than with central sensitization. Consequently, we recommend nonoral formulations of triptans, which do not necessarily have to be administered early during the migraine attack to provide efficacy. In conclusion, it is reassuring for migraineurs that it is worthwhile taking their medication in an appropriate formulation even if they have not been able to do so early in the course of the attack.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426264     DOI: 10.1111/j.1468-2982.2005.00999.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  10 in total

Review 1.  Non-oral formulations of triptans and their use in acute migraine.

Authors:  Carl G H Dahlöf
Journal:  Curr Pain Headache Rep       Date:  2005-06

2.  Allodynia as a complication of migraine: background and management.

Authors:  William B Young
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 3.  Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.

Authors:  Andrea Stephanie Link; Anikó Kuris; Lars Edvinsson
Journal:  J Headache Pain       Date:  2008-01-23       Impact factor: 7.277

4.  Primary Headache Disorders: Focus on Migraine.

Authors:  Anish Bahra
Journal:  Rev Pain       Date:  2011-12

5.  Migraine headache is present in the aura phase: a prospective study.

Authors:  Jakob M Hansen; Richard B Lipton; David W Dodick; Stephen D Silberstein; Joel R Saper; Sheena K Aurora; Peter J Goadsby; Andrew Charles
Journal:  Neurology       Date:  2012-10-31       Impact factor: 9.910

Review 6.  Cutaneous allodynia and migraine: another view.

Authors:  Carl Dahlöf
Journal:  Curr Pain Headache Rep       Date:  2006-06

7.  Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.

Authors:  Anna Ferrari; Diego Pinetti; Alfio Bertolini; Ciro Coccia; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

Review 8.  Are the current IHS guidelines for migraine drug trials being followed?

Authors:  Anders Hougaard; Peer Tfelt-Hansen
Journal:  J Headache Pain       Date:  2010-10-08       Impact factor: 7.277

9.  Vascular Contributions to Migraine: Time to Revisit?

Authors:  Bianca N Mason; Andrew F Russo
Journal:  Front Cell Neurosci       Date:  2018-08-03       Impact factor: 5.505

10.  Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.

Authors:  Haiyang Xu; Wei Han; Jinghua Wang; Mingxian Li
Journal:  J Headache Pain       Date:  2016-12-12       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.